Cardiovascular Systems Stock

Cardiovascular Systems ROE

Delisted

The Return on Equity (ROE) of Cardiovascular Systems (CSII) as of Aug 26, 2026 is -14.80 %. In the previous year, Return on Equity (ROE) was -4.95 % — a change of 198.88% (lower).

ROE

-14.80 %

YoY

198.88%

Last updated:

In 2026, Cardiovascular Systems's return on equity (ROE) was -14.80 %, a 198.88% increase from the -4.95 % ROE in the previous year.

The Cardiovascular Systems ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
-23.67 USD
Jan 1, 2016
-55.53 USD
Jan 1, 2017
-1.51 USD
Jan 1, 2018
1.27 USD
Jan 1, 2019
-0.17 USD
Jan 1, 2020
-10.13 USD
Jan 1, 2021
-4.95 USD
Jan 1, 2022
-14.80 USD
The Cardiovascular Systems ROE history
YEARROEYoY
-14.80 %+198.88%
-4.95 %-51.12%
-10.13 %+5,778.74%
-0.17 %-113.54%
1.27 %-184.11%
-1.51 %-97.27%
-55.53 %+134.56%
-23.67 %+1.82%
-23.25 %
Access this data via the Eulerpool API

Cardiovascular Systems Stock analysis

What does Cardiovascular Systems do? Cardiovascular Systems Inc. (CSI) is a US medical technology company founded in 1989. The company is headquartered in St. Paul, Minnesota and employs approximately 1,000 employees worldwide. CSI develops, manufactures, and distributes innovative devices for the treatment of vascular diseases. The business model of CSI is based on the development and marketing of medical devices for minimally invasive treatment of vascular diseases. The company generates a significant portion of its revenues through the sale of its products to hospitals and specialized healthcare facilities. Additionally, CSI also offers training and educational programs for doctors and medical personnel to optimize the use of their devices. CSI operates in two main segments: peripheral arterial disease (PAD) and coronary heart disease (CHD). The PAD segment includes devices for the treatment of vascular diseases outside of the heart, such as peripheral arterial occlusive disease (PAOD). This includes the Diamondback-360® catheter and the Stealth 360® catheter, both used for plaque ablation in the arteries. The CHD segment focuses on the treatment of heart diseases such as coronary artery disease (CAD). This includes the Orbital Atherectomy System (OAS), a device that can reduce the use of stents in patients with more severe coronary artery narrowings. CSI's core product is the Diamondback-360® catheter, which was approved by the US Food and Drug Administration (FDA) in 2013. This device consists of a rotating catheter inserted into the artery to remove plaque causing vessel narrowing. The Diamondback-360 catheter is used for the treatment of PAD and has the potential to significantly improve patients' quality of life. Another important product from CSI is the Orbital Atherectomy System (OAS), used for the treatment of CAD. The OAS system is a rotating catheter that can remove plaque in the coronary arteries to improve blood flow. The use of OAS can potentially avoid costly and invasive procedures such as coronary angiography or bypass. In summary, Cardiovascular Systems Inc. is a leading company in the development and production of innovative devices for minimally invasive treatment of vascular diseases. The company specializes in two main segments, peripheral arterial disease and coronary heart disease. With products like the Diamondback-360 catheter and the Orbital Atherectomy System, CSI has established itself as a reliable provider of high-quality medical devices. Through training and educational programs, CSI also contributes to improving medical care and the development of treatment methods. Cardiovascular Systems is one of the most popular companies on Eulerpool.

ROE Details

Decoding Cardiovascular Systems's Return on Equity (ROE)

Cardiovascular Systems's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Cardiovascular Systems's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Cardiovascular Systems's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Cardiovascular Systems’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Cardiovascular Systems stock

Return on Equity (ROE) of Cardiovascular Systems is -14.80 % in 2026.

Return on Equity (ROE) of Cardiovascular Systems changed from -4.95 % to -14.80 %, representing a 198.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Cardiovascular Systems since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Cardiovascular Systems with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Cardiovascular Systems

All Key Metrics — Cardiovascular Systems